A 2-part Phase 1/2 Open-label Trial on ODM-212 | stella

Learn Data Labs For Researchers Find trials matched to me

Learn Data Labs For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A 2-part Phase 1/2 Open-label Trial on ODM-212 | stella

Back to Mesothelioma trials

Recruiting

Plain-English translation of NCT07563738 on ClinicalTrials.gov ↗ · Source last updated May 2026 · How we translate trials

Read our Mesothelioma research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(2 sites)

United States

NEXT Oncology, Irving, Texas

NEXT Oncology Virginia, Fairfax, Virginia

Key details

Phase

Safety & dosing / Early efficacy

Sponsor

Orion Corporation, Orion Pharma

Enrollment target

~229 participants

Started

March 2026

Primary completion

September 2029

Age range

18 Years and older

Last updated on clinicaltrials.gov in May 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Clinical Study Director

Orion Corporation, Orion Pharma

View full record on ClinicalTrials.gov

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.